Literature DB >> 6130180

Beta-adrenergic blockers: ocular penetration and binding to the uveal pigment.

M Araie, M Takase, Y Sakai, Y Ishii, Y Yokoyama, M Kitagawa.   

Abstract

The ocular penetration of two beta-adrenergic blockers, befunolol and timolol, was studied using albino and pigmented rabbits. A 1% ophthalmic solution of 14C-befunolol hydrochloride or 14C-timolol maleate was instilled in one eye of nonsedated rabbits, and the concentrations of radioactive material in the ocular tissues were determined at various intervals. In the albino rabbit, the time courses of the concentration changes in the cornea and aqueous humor could be analyzed on the basis of a compartment theory, and the following coefficients were calculated using a computer; i.e., permeability of the corneal epithelium (kep), the distribution volume in the anterior chamber (Va), the cornea-aqueous transfer coefficient in reference to the corneal volume (kc.ca), the aqueous-cornea transfer coefficient in reference to Va (ka.ac), the loss rate from the anterior chamber (ko) and the steady state distribution ratio between the aqueous and cornea (rac). The following values were obtained for befunolol: kep--2.6 x 10(-3) cm hr-1, kc.ca--0.51 hr-1, ka.ac--0.18 hr-1, ko--2.7 hr-1, Va--250 microliters and rac--0.9. Those of timolol were as follows: kep--2.3 x 10(-3) cm hr-1, kc . ca--0.82 hr-1 and ko--2.5 hr-1. The estimates for Va and rac could not be calculated from the data obtained in the timolol experiment. Assuming that Va and rac for befunolol were also applicable for timolol, ka.ac for timolol was calculated to be 0.25 to 0.29 hr-1. The beta-adrenergic blockers tested here penetrated the cornea rather easily and they were lost from the anterior chamber mainly by diffusion, probably into the blood circulation through the anterior uvea. The data obtained in the pigmented rabbit indicated that these beta-adrenergic blockers are bound to the melanin-containing ocular tissues and are released from there very slowly. It is suggested that in heavily pigmented subjects, beta-adrenergic blockers might be less effective after short-term use and, furthermore, intraocular binding may occur after long-term use.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6130180

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  8 in total

1.  Neuroprotective effect of latanoprost on rat retinal ganglion cells.

Authors:  Hideyo Kudo; Toru Nakazawa; Masahiko Shimura; Hidetoshi Takahashi; Nobuo Fuse; Kenji Kashiwagi; Makoto Tamai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

2.  Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes.

Authors:  Chandrasekar Durairaj; James E Chastain; Uday B Kompella
Journal:  Exp Eye Res       Date:  2012-03-13       Impact factor: 3.467

Review 3.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

4.  The contralateral reduction of intraocular pressure by timolol.

Authors:  C N Dunham; R F Spaide; G Dunham
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

5.  Glaucoma Treatment Outcomes in Open Angle Glaucoma Patients of African Descent.

Authors:  Brent Siesky; Alon Harris; Aditya Belamkar; Ryan Zukerman; Avery Horn; Alice Verticchio Vercellin; Kristen A Mendoza; Paul A Sidoti; Francesco Oddone
Journal:  J Glaucoma       Date:  2022-03-29       Impact factor: 2.290

6.  Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells.

Authors:  Masahiko Ayaki; Atsuo Iwasawa; Yoichi Inoue
Journal:  Clin Ophthalmol       Date:  2010-10-21

7.  The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.

Authors:  Antonia M Joussen; Sebastian Wolf; Peter K Kaiser; David Boyer; Thomas Schmelter; Rupert Sandbrink; Oliver Zeitz; Gesa Deeg; Annett Richter; Torsten Zimmermann; Joachim Hoechel; Ulf Buetehorn; Walter Schmitt; Brigitte Stemper; Michael K Boettger
Journal:  Br J Clin Pharmacol       Date:  2018-11-25       Impact factor: 4.335

8.  A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells.

Authors:  Yoo Chun Kim; Henry T Hsueh; Matthew D Shin; Cynthia A Berlinicke; Hyounkoo Han; Nicole M Anders; Avelina Hemingway; Kirby T Leo; Renee Ti Chou; HyeYoung Kwon; Matthew B Appell; Usha Rai; Patricia Kolodziejski; Charles Eberhart; Ian Pitha; Donald J Zack; Justin Hanes; Laura M Ensign
Journal:  Drug Deliv Transl Res       Date:  2021-04-26       Impact factor: 4.617

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.